Regina Barragan-Carrillo, MD, discusses findings from a large population-based study which found there to be significantly higher rates of nephrectomy among patients with renal cell carcinoma who had received prior thymectomy vs the incidence of nephrectomy overall.
Regina Barragan-Carrillo, MD, medical oncologist, postdoctoral fellow, Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, discusses findings from a large population-based study which found there to be significantly higher rates of nephrectomy among patients with renal cell carcinoma (RCC) who had received prior thymectomy vs the incidence of nephrectomy overall.
Transcription:
0:10 | For the end points, we tested for the rate of nephrectomies, or renal cell diagnosis specifically. How we did this and how we chose that is because of the methodology we had available. We used the [California Office of Statewide Health Planning and Development (OSHPD)] database, which is the standard for the office of statewide planning and development which is a database based in California [and] accounts for all the procedures that are done in the inpatient and outpatient settings, and also for all ER visits. What we have seen with the information available are the procedures through the CPT and ICD-9/10 codes.
0:49 | What we decided is to use the coding for thymectomy and the coding for nephrectomy to identify both groups. For example, the rate we have in the state of California accounting for all adult patients, meaning 40 years or older, the rate we have for nephrectomy for renal cell carcinoma is around 0.2%. The rate we noticed in those patients who had previously undergone a thymectomy was 0.56%, which is more than double what we would have expected for the state of California.
1:26 | One might raise the question, and I think it is a valid question, is whether there was a risk of bias in the selection of the population because these are patients who are already under certain scrutiny because of their past surgical history. We included in our analysis, another 3 surgical procedures, which were a cholecystectomy, a hip arthroscopy, and a knee arthroscopy. In all 3 sub-populations who had undergone those procedures and afterwards required nephrectomy for RCC, the rates for RCC after diagnosis were also pretty similar to what we saw in the overall population, which were around 0.20%. Which also, historically, are the numbers that make sense in that regard. The difference between the patient with a prior time made to me was quite clear to us.
2:20 | This is only hypothesis generating. We still need to make a lot of efforts to understand whether there is an association of causation between those 2, but at least it raises the question to know whether patients that are in this nonclassical immunosuppressive state who have a higher risk to develop other secondary malignancies. We ask the clinical team as the healthcare providers could appropriately counsel these patients during their follow-up.
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
Beckermann and Participants Discuss Second-Line ccRCC Options
January 22nd 2025During a Case-Based Roundtable® event, Kathryn E. Beckermann, MD, PhD, discussed second-line regimens with event participants depending on their own practice and trial data for a patient with clear cell renal cell carcinoma.
Read More
Beyond the First-Line: Economides on Advancing Therapies in RCC
February 1st 2024In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
Listen
Enasidenib Shows Promise as Post-Transplant Maintenance in IDH2-Mutated AML
January 7th 2025Amandeep Salhotra, MD, discussed the background and findings from a pilot trial evaluating enasidenib as post-hematopoietic stem cell transplant maintenance therapy for IDH2-mutated acute myeloid leukemia treatment.
Read More
Considering How Favorable Risk Affects Treatment in ccRCC
January 3rd 2025During a Case-Based Roundtable® event, Daniel J. George, MD, discusses how often community oncology participants see patients with favorable-risk vs intermediate- or high-risk RCC, and how it changes their treatment options.
Read More